FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592512313> ?p ?o ?g. }

• W2592512313 endingPage "41640" @default.
• W2592512313 startingPage "41631" @default.
• W2592512313 abstract "Although most patients with ALK-positive non-small-cell lung cancer (NSCLC) who benefit from treatment with crizotinib ultimately develop progressive disease (PD), continuing crizotinb beyond the initial PD (CBPD) in these patients may be beneficial. In this study, we investigated whether Chinese patients with advanced ALK-positive NSCLC benefit from CBPD, and whether any factors are predictive of a longer post-initial progression-free survival time (PFS2).Data on 33 patients with ALK-positive NSCLC who achieved disease control with crizotinib were analyzed retrospectively. The impact of continued crizotinib therapy on the patients' PFS2 time was assessed after adjusting for potential confounding factors.With initial crizotinib therapy, the objective response rate (ORR) and median PFS time (PFS1) in the 33 patients were 63.6% and 8.6 months, respectively. With continued crizotinib therapy after documentation of PD, the median PFS2 for all 33 patients was 16 weeks, and in those with CNS progression but systemic disease control it was 30 weeks. Patients who received local therapy after disease progression had a significantly longer PFS2 compared with those who did not (P = 0.039). Multivariable Cox regression analysis showed that the PFS1 with initial crizotinib treatment and local therapy were independent predictors of PFS2.This study provides further evidence of the benefit of continuing crizotinib therapy in Chinese patients with progressive ALK-positive NSCLC. Patients with a longer PFS1 and those who received local brain therapy would have a longer period of continuing crizotinib." @default.
• W2592512313 created "2017-03-16" @default.
• W2592512313 creator A5008311955 @default.
• W2592512313 creator A5013715130 @default.
• W2592512313 creator A5014708668 @default.
• W2592512313 creator A5020443335 @default.
• W2592512313 creator A5026633464 @default.
• W2592512313 creator A5046131158 @default.
• W2592512313 creator A5046341345 @default.
• W2592512313 creator A5089474742 @default.
• W2592512313 date "2017-03-04" @default.
• W2592512313 modified "2023-09-26" @default.
• W2592512313 title "Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer" @default.
• W2592512313 cites W1946770989 @default.
• W2592512313 cites W1964973266 @default.
• W2592512313 cites W1973947576 @default.
• W2592512313 cites W1974903221 @default.
• W2592512313 cites W1981676561 @default.
• W2592512313 cites W2018023615 @default.
• W2592512313 cites W2019607817 @default.
• W2592512313 cites W2030227571 @default.
• W2592512313 cites W2050249255 @default.
• W2592512313 cites W2074782882 @default.
• W2592512313 cites W2096156234 @default.
• W2592512313 cites W2099530756 @default.
• W2592512313 cites W2103295992 @default.
• W2592512313 cites W2111724182 @default.
• W2592512313 cites W2112854176 @default.
• W2592512313 cites W2113327188 @default.
• W2592512313 cites W2128208856 @default.
• W2592512313 cites W2130488043 @default.
• W2592512313 cites W2134787029 @default.
• W2592512313 cites W2139110945 @default.
• W2592512313 cites W2139483106 @default.
• W2592512313 cites W2140333474 @default.
• W2592512313 cites W2147038864 @default.
• W2592512313 cites W2151116840 @default.
• W2592512313 cites W2159587676 @default.
• W2592512313 cites W2159655211 @default.
• W2592512313 cites W2160304102 @default.
• W2592512313 cites W2164514441 @default.
• W2592512313 cites W2208535430 @default.
• W2592512313 cites W2218718059 @default.
• W2592512313 cites W2272984102 @default.
• W2592512313 cites W2324520777 @default.
• W2592512313 doi "https://doi.org/10.18632/oncotarget.15892" @default.
• W2592512313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5522304" @default.
• W2592512313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28427213" @default.
• W2592512313 hasPublicationYear "2017" @default.
• W2592512313 type Work @default.
• W2592512313 sameAs 2592512313 @default.
• W2592512313 citedByCount "10" @default.
• W2592512313 countsByYear W25925123132018 @default.
• W2592512313 countsByYear W25925123132019 @default.
• W2592512313 countsByYear W25925123132020 @default.
• W2592512313 countsByYear W25925123132021 @default.
• W2592512313 countsByYear W25925123132022 @default.
• W2592512313 crossrefType "journal-article" @default.
• W2592512313 hasAuthorship W2592512313A5008311955 @default.
• W2592512313 hasAuthorship W2592512313A5013715130 @default.
• W2592512313 hasAuthorship W2592512313A5014708668 @default.
• W2592512313 hasAuthorship W2592512313A5020443335 @default.
• W2592512313 hasAuthorship W2592512313A5026633464 @default.
• W2592512313 hasAuthorship W2592512313A5046131158 @default.
• W2592512313 hasAuthorship W2592512313A5046341345 @default.
• W2592512313 hasAuthorship W2592512313A5089474742 @default.
• W2592512313 hasBestOaLocation W25925123131 @default.
• W2592512313 hasConcept C121608353 @default.
• W2592512313 hasConcept C126322002 @default.
• W2592512313 hasConcept C143998085 @default.
• W2592512313 hasConcept C2776232967 @default.
• W2592512313 hasConcept C2776256026 @default.
• W2592512313 hasConcept C2778347629 @default.
• W2592512313 hasConcept C2779134260 @default.
• W2592512313 hasConcept C2779177807 @default.
• W2592512313 hasConcept C2779422266 @default.
• W2592512313 hasConcept C2781230642 @default.
• W2592512313 hasConcept C71924100 @default.
• W2592512313 hasConcept C81729549 @default.
• W2592512313 hasConceptScore W2592512313C121608353 @default.
• W2592512313 hasConceptScore W2592512313C126322002 @default.
• W2592512313 hasConceptScore W2592512313C143998085 @default.
• W2592512313 hasConceptScore W2592512313C2776232967 @default.
• W2592512313 hasConceptScore W2592512313C2776256026 @default.
• W2592512313 hasConceptScore W2592512313C2778347629 @default.
• W2592512313 hasConceptScore W2592512313C2779134260 @default.
• W2592512313 hasConceptScore W2592512313C2779177807 @default.
• W2592512313 hasConceptScore W2592512313C2779422266 @default.
• W2592512313 hasConceptScore W2592512313C2781230642 @default.
• W2592512313 hasConceptScore W2592512313C71924100 @default.
• W2592512313 hasConceptScore W2592512313C81729549 @default.
• W2592512313 hasIssue "25" @default.
• W2592512313 hasLocation W25925123131 @default.
• W2592512313 hasLocation W25925123132 @default.
• W2592512313 hasLocation W25925123133 @default.
• W2592512313 hasLocation W25925123134 @default.
• W2592512313 hasOpenAccess W2592512313 @default.
• W2592512313 hasPrimaryLocation W25925123131 @default.

• next